Variation in chitotriosidase values measured on simultaneous samples by two commercial laboratories

American Journal of Hematology

Volumn 88, Issue 11, 2013, Pages 980-980

  Sirrs, Sandra ^a,b   Casey, Robin ^c   Patterson, Mary Anne ^d   Mcneil, Colleen ^c   Paquin, Wendy ^a   Amato, Dominick ^d,e  

^a Adult Metabolic Diseases Clinic   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d MOUNT SINAI HOSPITAL   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CHITOTRIOSIDASE; IMIGLUCERASE; VELAGLUCERASE ALFA;

ENZYME REPLACEMENT; GAUCHER DISEASE; HUMAN; LABORATORY DIAGNOSIS; LETTER; MEASUREMENT; PRIORITY JOURNAL; SAMPLE;

EID: 84886284818     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23542     Document Type: Letter

References (4)

1. Gonzalez DE, Turkia HB, Lukina EA, et al. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol 2013;88:166-171.
2. Turkia HB, Gonzalez DE, Barton NW, et al. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol 2013;88:179-184.
3. Zimran A, Pastores GM, TylkiSzymanska A, et al. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol 2013;88:172-178.
4. Hollak CE, van Weely S, van Oers MH, Aerts, JM, Marked elevation of plasma chitotriosidase activity, a novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-1292.